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Background: Dipeptidyl peptidase IV, a multifunctional serine protease, is implicated in regulation of malignant
transformation, promotion and further progression of cancer, exerting tumor-suppressing or even completely
opposite - tumor-promoting activities.
The aim of present research was to determine the serum DPPIV activity, as well as the percentages of CD26+
lymphocytes, CD26+ overall white blood cells and the mean fluorescence intensity of CD26 expression on
lymphocytes in patients with melanoma, people with vitiligo and in healthy controls.
Methods: The activity of DPPIV in serum was determined by colorimetric test. Expression of DPPIV (as CD26) on
immunocompetent peripheral white blood cells was done using flow cytometry analysis.
Results: Data from our study show for the first time statistically significant decrease: in the serum DPPIV activity, in
the percentage of CD26+ overall white blood cells and in the percentage of lymphocytes in patients with
melanoma in comparison to healthy control people. In addition, significantly lower serum DPPIV activity was found
in the group of patients with melanoma in relation to people with vitiligo too.
Conclusion: This study indicates the need for exploring the cause and the importance of the disturbances in the
serum DPPIV activity and in the CD26 expression on immunocompetent cells in complex molecular mechanisms
underlying the development and progression of melanoma.
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Elucidation of molecular mechanisms involved in car-
cinogenesis and understanding the complex crosstalk
between immunity and cancer represent one of the cru-
cial steps in development of novel, better approaches in
prevention, diagnosis and therapy of malignant dis-
eases. Many recent studies focused on biology of cancer
indicate the prominent role of dipeptidyl peptidase IV
(DPPIV or CD26) in initial steps of malignant trans-
formation, promotion and progression of tumors, act-
ing as a tumor suppressor or even tumor activator.* Correspondence: juranicz@ncrc.ac.rs
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reproduction in any medium, provided the orMoreover, DPPIV is implicated in the control of diverse
biological processes, especially immune functions and
inflammation [1-4].
By cleaving the dipeptides from N- terminal end of
peptides and polypeptides that have proline or alanine
in the second position, DPPIV controls the activity of
many bioactive molecules, including cytokines and
chemokines, incretins and gastrointestinal hormones,
vasoactive peptides and neuropeptides [1-3]. Besides
its enzymatic activity, DPPIV acts as receptor for plas-
minogen type 2 and adenosine deaminase (ADA),
interacts with chemokine receptor CXCR4 and with
mannose 6-phosphate/insulin-like growth factor II re-
ceptor. Furthermore, DPPIV exerts costimulatory
function by association with tyrosine phosphatasetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cellular matrix, such as collagen and fibronectin, points
to its role in adhesion, invasion and metastasis of cancer
cells [1-3,5]. Its involvement in regulation of apoptosis
has been reported too [1] and references cited therein.
Data from many reports show association of altered
CD26 expression levels on the cell surface as well as
changes in DPPIV/CD26 activity or sCD26 levels, with
various types of cancer [1-12]. Tumor-suppressing activ-
ity of DPPIV is supported by facts that decrease and loss
of DPPIV expression and activity are found in microen-
vironments of specific tumors and also in systemic cir-
culation [2]. Decrease in DPPIV is shown in melanoma,
prostatic, endometrial, colorectal, hematological and
renal cancers, and in lung and skin squamous cell car-
cinomas. On the contrary, elevated DPPIV expression
and/or activity are related to thyroid follicular carcin-
oma, astrocytic tumors, gastrointestinal stromal tumors,
T and B lymphomas and leukemias, revealing the tumor-
promoting activities of this molecule, as reviewed by
Cordero et al. [2] and references cited therein. It is very
important to note that lower serum DPPIV enzymatic
activity, related with impaired immune functions, is
found in patients with various types of hematological
malignancies and different solid malignant tumors, in-
cluding oral cancer, gastric carcinoma, colorectal cancer
and thyroid cancer. Increase in serum DPPIV activity,
associated with enhanced immunity, occurs in hepatic
cancer and in some hematological neoplasmas [2] and
references cited therein.
Decreased expression of CD26 during malignant trans-
formation of melanocytes and even the absence of this
molecule on primary and metastatic melanoma cells is
already proved [13-17], but still there are no data on the
extent of the expression of this molecule on immuno-
competent cells and its serum activity in melanoma
patients. These missing facts about DPPIV, implicated
in regulation of tumorigenesis and immune functions,
could be significant especially because melanoma is
highly immunogenic malignant tumor [18]. On the
other hand, it is documented that 10% of patients with
melanoma develop hypopigmentation of the skin that
resembles vitiligo, an autoimmune dermatological dis-
order. In addition, enhanced antitumor immune response
observed in mentioned melanoma patients is considered
to be connected with a better prognosis [18,19].
Assessment of changes in the DPPIV activity in patient's
sera and in the percentages of CD26+ immunocompetent
cells was done with the aim to clarify the possible role of
DPPIV in development and progression of melanoma.
Regarding the possible connection between melanoma
and vitiligo, it would be important to examine if there are
any changes in DPPIV expression levels on lymphocytes
and serum activity in people with vitiligo.Methods
Patients
This research involved 64 patients with melanoma
(60.48 ± 14.81 (mean age ± SD), age range 23–86 years;
34 males and 30 females) and 16 people with vitiligo
(47.62 ± 11.56 (mean age ± SD), age range 26–64 years; 5
males and 11 females). In addition, 6 patients with other
malignant skin tumors (64.83 ± 14.34 (mean age ± SD),
age range 37–75 years; 4 males and 2 females) and 6
patients with benign skin changes (53.50 ± 22.92 (mean
age ± SD), age range 16–75 years; 1 male and 5 females)
were also included in the study. Samples were obtained
before surgical resection of the tumor. It should be
noted that 37 melanoma patients were with metastatic
disease. The control group consisted of 40 apparently
healthy donors (39.13 ± 10.65 (mean age ± SD), age range
24–62 years; 14 males and 26 females). The protocol of
the study was approved by the Ethics Committee of the
Institute of Oncology and Radiology of Serbia. Written
informed consent was obtained from each patient.
DPPIV activity in serum
The activity of DPPIV in patient’s serum was determined
by direct photometric method adapted to 96-well micro-
titer plates and according to the procedure described by
Jarmolowska et al. [20], but modified to some extent. In
serum samples and their blanks were added 50 μL of
0.3 M Gly/NaOH buffer (pH 8.7), 20 μL of 1.5 mM Gly-
Pro-p-nitroanilide p-toluensulfonate (DPPIV substrate,
Sigma G2901) and 50 μL of distilled water. Samples of
standard contained 20 μL of 1.5 mM p-nitroaniline
(Sigma N2128) instead of substrate and their blanks con-
tained 20 μL of water. After 30 min of incubation at 37°C,
50 μL of chilled (4°C) 1 M acetate buffer (pH 4.2), was
added to blanks of serum samples in order to prevent the
enzymatic reaction. Then 10 μL of serum was added to
serum samples and their blanks. In standard samples and
standard’s blanks 10 μL of water was added. Plates were
incubated for another 30 min at 37°C. Enzymatic reaction
was stopped by adding 50 μL of chilled (4°C) 1 M acetate
buffer (pH 4.2) in samples that contained serum. Samples
of standard and their blanks also contained the same vol-
ume of acetate buffer. The absorbance was measured at
405 nm. DPPIV activity in serum was calculated according
to the formula:
Enzyme activity ¼ A serum sample A blank of serumð
sample=A standard A blank of standardÞ
 100
Enzyme activity : IU=L ¼ 1 μM=min=L of serum
All experiments were done in triplicate. Cut-off values
were (Xav ± SD) IU/L.
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Expression levels of CD26 on white blood cells were
evaluated by flow cytometry analysis. Briefly, 50 μL of
whole blood was added to 2.5 μL (0.05 mg/mL) of solu-
tion of Ab, reaction mixture was vortexed, and incu-
bated in the dark for 15 min. Then 800 μL of lysing
solution was added, vortexed and incubated in the dark
for 10 min, centrifuged for 5 min at 1600 rpm. Cell sam-
ples were washed two times and at the end 200 μL of
cell fix or cell wash solution was added. Monoclonal
antibody specific for CD26 was PE-stained (Becton
Dickinson Immunocytometry Systems, CA, USA, catalog
number 340423). Expression of CD26 on cells, observed
mostly on lymphocytes, (sorted by physical gating) was
determined using a FACSCalibur flow cytometer (BD
Biosciences Franklin Lakes, NJ, USA). Acquired data were
analyzed using CELLQuest Software (BD Biosciences).
Obtained data were presented not only as the expres-
sion on lymphocytes, but also additionally as percent-
age of CD26 expression on total white blood cell pool
(lymphocytes, monocytes and granulocytes). Cut-off
values for analyzed parameters were (Xav ± SD).
Statistical methods
Statistical significance of differences in studied parameters
between examined groups was estimated using Fisher
exact test, Kruskal Wallis test, Wilcoxon rank sum test
and Wilcoxon rank sum test with continuity correction.
Normal distributions of parameters were tested using the
Kolmogorov-Smirnov test and Shapiro-Wilk test. For ana-
lyses was used statistical programme R version 2.14.1
(2011-12-22) Copyright (C) 2011 The R Foundation for
Statistical Computing, ISBN 3-900051-07-0. Bonferroni
correction used for the determination of the statistical
significance of results obtained, set up the value of
(p < 0.05/10) as the limit.
An abnormal elevation of the value obtained for each
analyzed parameter was defined as any value above the
mean value for the control healthy people group plus
the standard deviation and an abnormal reduction as
any value below the mean value for the control group
minus the standard deviation.
Results
Activity of DPPIV in serum
Data from the present research show that there is a sta-
tistically significant decrease in the serum DPPIV activity
in patients with melanoma in comparison to healthy
controls (p < 0.0004), as well as in comparison to people
with vitiligo (p < 0.0004). These results are presented in
Table 1 and on Figure 1. There was no difference in the
obtained values for DPPIV activity in serum between
vitiligo and healthy control groups. Lower serum DPPIV
activity was also found in patients with other malignantskin tumors compared to people with vitiligo and to
healthy controls.
It should be noted that 30 out of 62 analyzed patients
with melanoma had decreased DPPIV activity in serum,
while only 4 melanoma patients had increased DPPIV
serum activity (Figure 1). Concerning the presence of
metastatic disease, 13 out of 27 melanoma patients with-
out metastatic disease had decreased DPPIV activity,
while 17 out of 35 melanoma patients with metastases
had decreased activity of DPPIV in serum. Enhanced
DPPIV serum activity was observed in 3 patients with
metastases and only in one melanoma patient without
metastatic disease.
On the other hand, only 1 out of 16 persons with viti-
ligo had diminished DPPIV activity, as well as 6 out of
40 healthy controls. In addition, 4 people with vitiligo
and 7 healthy controls were with higher DPPIV activity.
Expression of CD26 on immunocompetent peripheral
white blood cells
Regarding the expression levels of DPPIV (as CD26) on
lymphocytes, no significant differences in the percen-
tages of CD26+ lymphocytes (Figure 2B), and in the
values for mean fluorescence intensity (MFI) of CD26
expression on lymphocytes (Figure 2C) were found be-
tween the melanoma patients, people with vitiligo and
healthy control subjects. However, there is a statistically
significant decrease in the percentage of CD26+ overall
(white peripheral blood) cells in patients with melanoma
in relation to healthy control people (p < 0.00006) as
seen in Table 1 and on Figure 2A. In the group of 6
patients with other malignant skin tumors decrease in
the percentage of CD26+ overall cells was observed
when compared to healthy controls, although this differ-
ence had not statistical significance (Wilcoxon rank sum
test: W=61; p = 0.055). Furthermore, a higher frequency
of patients with melanoma showed decreased percen-
tages of CD26+ overall cells (26 out of 64, cut-off point
6.00% (Xav-SD), as seen on Figure 2A.
Since lymphocyte pool is considered as one of the
main sources of soluble DPPIV in serum, the percen-
tages of lymphocytes in examined groups were deter-
mined too. It is very important to stress that there is a
statistically significant decrease in the percentage of lym-
phocytes in patients with melanoma in comparison to
healthy controls (p < 0.00003), (Table 1 and Figure 2D).
Group of people with vitiligo had higher lymphocyte
percentage than the group of patients with melanoma,
but this difference was not significant (Wilcoxon rank
sum test with continuity correction: W=321; p = 0.048).
Additionally, 29 out of 64 patients with melanoma had
decreased percentage of lymphocytes, in contrast to 5 out
of 40 healthy controls and none of people with vitiligo
with lower lymphocyte percentage. The cut-off values for
Table 1 Activity of DPPIV in serum, % of CD26+ lymphocytes and % of CD26+ white blood cells, mean fluorescence
intensity (MFI) of CD26 expression on lymphocytes and % of lymphocytes in healthy controls, people with vitiligo,
patients with melanoma, and in patients with other malignant skin tumors and benign changes of the skin











Healthy controls 40 27.03 ± 7.00 50.33 ± 11.85 11.26 ± 5.26 278.41± 138.82 20.65 ± 8.48
Vitiligo 16 29.51 ± 7.24 48.04 ± 10.02 8.41 ± 3.30 690.29± 907.96 16.50 ± 4.51
Melanoma 64 21.81 ± 6.79 * 52.93 ± 10.77 7.16 ± 3.63 ** 377.21± 554.38 13.43 ± 6.13 ***
Melanoma without
metastatic disease
27 21.53 ± 6.74 53.24 ± 9.92 6.40 ± 3.28 409.51± 686.61 12.18 ± 5.91
Melanoma with
metastatic disease
37 22.02 ± 6.91 52.71 ± 11.49 7.71 ± 3.81 353.64± 442.73 14.35 ± 6.19
Other malignant
skin tumors
6 23.08 ± 8.28 47.17 ± 7.93 7.06 ± 3.28 235.73± 172.32 13.36 ± 6.02
Benign skin changes 6 27.32 ± 12.96 54.64 ± 10.78 9.19 ± 4.32 249.45± 237.82 15.77 ± 6.17
* p <0.0004 in comparison to healthy controls and to people with vitiligo.
** p < 0.00006 in comparison to healthy controls.
***p < 0.00003 in comparison to healthy controls.
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28.92% (Xav + SD), previously obtained from 41 healthy
control persons, including 40 involved in this study. On
the other hand, 15 out of 64 patients with melanoma had
increased MFI of CD26 lymphocytes expression and
among 15 people with vitiligo, 8 had increased MFI of
CD26 expression on lymphocytes.
Relationship between the serum DPPIV activity and CD26
expression
It should be mentioned that higher frequency of melan-
oma patients without metastatic disease had decreasedFigure 1 Serum DPPIV activity in healthy controls (C), in people with
other malignant skin tumors (MST) or benign skin changes (BS). Xav+
with borders represent melanoma patients without metastases, while green
disease. There is a statistically significant decrease in the DPPIV serum activ
(Wilcoxon rank sum test with continuity correction: W= 723; p < 0.0004) an
with continuity correction: W= 206; p < 0.0004).percentage of CD26+ overall cells (14 out of 27) and
decreased percentage of lymphocytes (16 out of 27) com-
pared to patients with metastatic disease (frequencies: 12
out of 37, and 13 out of 37, respectively). It is interesting
to note that 14 out of 30 melanoma patients who had
decreased serum DPPIV activity also had decreased per-
centage of CD26+ overall cells. There were 15 melan-
oma patients out of 30 who had decreased DPPIV
serum activity and lymphocyte percentage as well.
However, 6 out of 30 melanoma patients who had
decreased DPPIV serum activity showed an increased
percentage of CD26+ lymphocytes. Furthermore, 18 outvitiligo (V), in patients with melanoma (M), and in patients with
/−SD are cut off values obtained from healthy controls. Green circles
circles without borders represent melanoma patients with metastatic
ity in patients with melanoma in comparison to healthy controls
d as well as in relation to people with vitiligo (Wilcoxon rank sum test
Figure 2 (A) percentage of CD26+ overall white blood cells, (B) percentage of CD26+ lymphocytes, (C) mean fluorescence intensity
(MFI) of CD26 expression on lymphocytes and (D) percentage of lymphocytes, in healthy controls (C), in people with vitiligo (V), in
patients with melanoma (M), and in patients with other malignant skin tumors (MST) or benign skin changes (BS). Xav+/−SD are cut off
values obtained from healthy controls. Green circles with borders represent melanoma patients without metastases, while green circles without
borders represent melanoma patients with metastatic disease. There is a statistically significant decrease in the percentage of CD26+ overall
white blood cells, (Wilcoxon rank sum test with continuity correction: W= 679.5; p < 0.00006), as well as in the percentage of lymphocytes
(Wilcoxon rank sum test with continuity correction: W= 644.5; p < 0.00003) in patients with melanoma compared to healthy controls.
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of CD26+ overall cells had reduced percentage of
lymphocytes.
In contrast, only one person with vitiligo, disease with
autoimmune etiology, with decreased serum DPPIV ac-
tivity, had decreased percentage of CD26+ lymphocytes
and percentage of CD26+ overall cells, while percentage
of lymphocytes was in the range of reference values. In
addition, 2 out of 8 people with vitiligo with increased
MFI of CD26 expression on lymphocytes showed
increased DPPIV serum activity. Moreover, from the 15
out of 64 patients with melanoma with increased MFI of
CD26 lymphocytes expression, 6 showed decreased
DPPIV activity in serum.Discussion
Multifunctional regulatory molecule, dipeptidyl peptid-
ase IV plays an important role in tumorigenesis. De-
pending on the interaction with specific biomolecules,
implicated in initiation, promotion and progression of
cancer, and depending on the modulation of bioactive
peptides according to the intensity of expression, DPPIV
may exert tumor-suppressing activity, as well as com-
pletely opposite - tumor-promoting activity [2,4,5].
In the initial steps of pathogenesis of melanoma the
alterations in expression and activity of DPPIV might be
significant: a) During malignant transformation of mela-
nocytes into melanoma cells, down-regulation of DPPIV
expression and later complete loss of expression occurs
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2q24.2, interestingly this chromosome is altered in 35%
of melanoma specimens, indicating that loss of DPPIV
expression caused by deletion may be even related to
progression of melanoma; c) Induction of normal levels
of DPPIV expression in human melanoma cells trans-
fected with gene coding for the DPPIV caused loss of
characteristics of malignant cells and phenotype changes,
suggesting the tumor – suppressing properties of DPPIV
[17]; d) Results from one study showed decline in an in-
vasive potential of melanoma cell lines in which DPPIV
was reexpressed at levels similar to those in non-
transformed melanocytes [15]; e) Additionally, DPPIV
was identified as one of the potential markers for dis-
tinction between benign deep penetrating nevi and
melanoma [16].
Due to its role in regulation of immune, inflammatory
and neuroendocrine processes, disturbances in serum
DPPIV activity and/or expression are related to different
pathophysiological conditions [2,21-27]. For example,
lower activity of DPPIV in serum is found in patients
with diabetes mellitus, hypertension associated with
angioedema induced by angiotensin-converting enzyme
treatment, in disorders such as anxiety and depression,
in patients with autoimmune diseases and different
immune-mediated disorders, including rheumatoid arth-
ritis, systemic lupus erythematosus and inflammatory
bowel disease. On the other hand, increase in DPPIV
serum activity is related to liver disorders, osteoporosis,
infectious diseases and anorexia and bulimia. All men-
tioned details concerning the complexity of DPPIV
should be taken into account for better understanding of
its functions. Although it is suggested that activity of
DPPIV in serum may decrease with age due to enhanced
sialylation [2,3], absence of significant age influence on
serum DPPIV activity was documented as well [28,29].
In the group of healthy control persons, no significant
age-related differences in DPPIV serum activity were
noticed; 3 out of 6 healthy controls who had decreased
DPPIV activity were under the age of 30. It is important
to note that significant differences between obtained
reference values for serum DPPIV activity for healthy
persons could be seen in the literature, depending on
the experimental procedure and the number of exam-
ined subjects. Considering the cut-off values for DPPIV
activity in serum, obtained by analyzing 40 healthy con-
trol people, our results are in agreement with some of
the previously reported data, while at the same time are
in contrast to higher or lower values presented in other
research articles [2] and references cited therein, [29-32].
We report for the first time that there is a statistically
significant decrease in the serum DPPIV activity, in the
percentage of CD26+ overall white blood cells and in
the lymphocyte percentage in patients with melanoma incomparison to healthy control people. Apparently, de-
crease in the mentioned parameters observed in the
group of patients with melanoma is not dependent on
the presence of metastatic disease, since differences in
measured parameters were not statistically significant
between the subgroup of melanoma patients without
metastatic disease and the subgroup of patients with
metastatic disease. Significant decline in serum DPPIV
activity found in melanoma patients compared to
healthy controls might indicate its possible role in devel-
opment and progression of melanoma, but further re-
search needs to be done in order to fully elucidate the
cause and the importance of observed changes in DPPIV
activity. However, alterations in DPPIV serum activity
observed in the group of melanoma patients might be, at
least to some extent, attributed to other individually spe-
cific physiological and pathophysiological processes.
Decreased percentage of lymphocytes found in 29 out
of 64 examined patients with melanoma points to
impaired immune functions, which may affect the course
of this malignant disease. In this regard, one of the
approaches in the treatment of different forms of cancer
is immunotherapy, based on the use of immunomodula-
tory factors in order to enhance the antitumor immune
response, and those agents may elevate level of DPPIV
as well.
Changes in the DPPIV serum activity in patients with
melanoma associated with decrease in the percentage of
CD26+ white blood cells could be explained by signifi-
cant decrease in the lymphocyte percentage, caused by
tumor-specific immunosuppression or by alterations in
lymphocytes homing induced by changes in chemokine
gradients. Since cell surface CD26 associates with
extracellular ADA, changes in CD26 expression on lym-
phocytes might, at least in some part, influence their
overall number as a result of fact that ecto-ADA free
lymphocytes are not capable to catalyze and inactivate
potentially toxic adenosine to non-toxic inosine [1-3].
However, one explanation to be investigated could be
related to changes in the lymphocyte subsets, some
richer than another in CD26 expression.
Conclusions
Results from the present study show for the first time
statistically significant decrease in the serum DPPIV ac-
tivity, in the percentage of CD26+ overall white blood
cells and in the lymphocytes percentage in patients with
melanoma in comparison to healthy control people. In
addition, melanoma patients had significantly lower
levels of DPPIV serum activity than people with vitiligo.
Obtained data support the relationship between circulat-
ing DPPIV and the immune system and may suggest the
potential role of DPPIV in complex molecular mechan-
isms of melanoma pathogenesis. This study indicates the
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disturbances in the serum DPPIV activity and in the
CD26 expression on white blood cells in melanoma.
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